A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs Meeting Abstract


Authors: Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D.
Abstract Title: A multicenter, randomized phase 3 study of asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 TKIs
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: clinical trial; cml; tyrosine kinase inhibitor; chronic; myelogenous leukemia; asciminib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S286
End Page: S287
Language: English
ACCESSION: WOS:000483480700267
DOI: 10.1016/j.clml.2019.07.230
PROVIDER: wos
Notes: Meeting Abstract: CML-040 -- Source: Wos
Altmetric Score
MSK Authors
  1. Michael John Mauro
    134 Mauro